Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by stanleyon Mar 04, 2013 1:36pm
216 Views
Post# 21074761

RE: BIG PICTURE - BRD GOT MENTIONED @ PDAC

RE: BIG PICTURE - BRD GOT MENTIONED @ PDAC

Terry:

While not a astute on the POG & BRD pps as others on this board. There is a significant mention of the central banks buying of gold. There was a mention that the banks are on a paper printing rampage some of them could be using paper to buy the physical gold. How long would it take to replace Germany's gold? LOL Some are speculation that a certain Central Bank's gold (FN) has not been audited for many years as they do not want to prove that the gold is (allegedly) not there.

 

I thought that Hayward's mention of Brigus on Berman's call was significant in this POG down cycle. I believe that a long term speculator in BRD shares could see some upside when the BRD BFS/FFS or other combo with SAS is announces later this year.

https://www.sasgoldmines.com/s/PhotoGallery.asp

Hecla is now the owner of Aurizon versus the Alamos hostile offer. If Hecla has been watching ARZ for years, does the BRD trading pattern by B33 reflect a potential buyer capping the BRD PPS? Maybe maybe not. 

 

BWDIK? Today's SAS NR IMHO is VERY relevant to the development of Grey Fox going foward. Read the latest SAS investor presentation to see if they (BRD & SAS) are using the same data base for their maps. In their last presentation JP referred to Brigus as the "neighbour to the north". Today BRD is finally getting mentioned by name ... precluding the plagaristic path/tact that was being followed. i.e. BRD was not being referenced but was instead being ignored, neighbour to the north; but not by name. Could it be that BRD & SAS are finally at Option A + Option B (combination of the Grey Fox & Hislop North resources)?. If the Stock (BF) mill is being retrofitted with a SAG mill, SAS mentioned liberation/grinding issues with the ores hardness.

 

Cheers

Stanley

Bullboard Posts